Lin, Hui-Ming
Huynh, Kevin
Kohli, Manish
Tan, Winston
Azad, Arun A.
Yeung, Nicole
Mahon, Kate L.
Mak, Blossom
Sutherland, Peter D.
Shepherd, Andrew
Mellett, Natalie
Docanto, Maria
Giles, Corey
Centenera, Margaret M.
Butler, Lisa M. http://orcid.org/0000-0003-2698-3220
Meikle, Peter J.
Horvath, Lisa G. http://orcid.org/0000-0001-6842-9223
Funding for this research was provided by:
Cancer Institute NSW (10/TPG/1-04, 2018/TPG001)
Cancer Council NSW (PG 10-01)
Department of Health | National Health and Medical Research Council (GNT0614296)
U.S. Department of Health & Human Services | National Institutes of Health (RO1-CA212097)
Article History
Received: 19 October 2020
Revised: 10 January 2021
Accepted: 28 January 2021
First Online: 21 March 2021
Compliance with ethical standards
:
: AAA: Consultant—Astellas, Janssen, Novartis; Speakers Bureau—Astellas, Janssen, Novartis, Amgen; Honoraria—Astellas, Janssen, Novartis, Tolmar, Amgen, Pfizer, Telix; Scientific Advisory Board—Astellas, Novartis, Sanofi, Astra Zeneca, Tolmar, Pfizer, Telix; Research Funding—Astellas, Merck Serono, Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional). LGH: Research funding—Astellas; Travel sponsorship—Janssen, Pfizer; Honoraria—Imagion Biosystems. All remaining authors have declared no competing interests.